×
AllNewsImages Maps Videos Books
Search tools

Genkyotex’s setanaxib shows favourable safety profile in Phase I trial

Clinical Trials Arena
Doses up to 800mg/day were earlier analysed in a 24-week Phase II trial in PBC patients. Data from this trial showed that this dose of setanaxib...
58 months ago

This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis

Labiotech.eu
Genkyotex is not giving up after its lead candidate, GKT831, failed to meet the primary endpoint in a Phase II trial in patients with type 2...
41 months ago

Calliditas gets controlling stake, option to buy out Genkyotex and its failed PBC drug

Fierce Biotech
The biobucks payments are wedded to NOX inhibitor setanaxib (GKT831), Genkyotex' lead drug which is focused on PBC. PBC, previously known as...
63 months ago

Genkyotex cashes in €7.5m

European Biotechnology Magazine
French Genkyotex SA has secured an €7.5m gross financing to expand the scope of its Phase II product GKT831 in Primary Biliary Cholangitis...
87 months ago

Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months

GlobeNewswire
Yorkville continues to support Genkyotex and its development plansThe Company has purchased back from remaining existing convertible notes...
75 months ago